H1614
Group 3 Pulmonary Hypertension (PH-ILD)
Phase 2Active
Key Facts
About Halo Biosciences
Halo Biosciences is a private, clinical-stage biotech pioneering a novel approach to treating inflammatory and fibrotic diseases by targeting pathological remodeling of the extracellular matrix, specifically hyaluronan (HA). Its lead candidate, H1614, is a reformulation of 4-methylumbelliferone (4-MU) in Phase 2 development for Group 3 pulmonary hypertension. The company's strategy is to leverage HA pathway inhibition to address the underlying inflammation, fibrosis, and vascular dysfunction in high-need pulmonary and hepatic indications. Halo represents a promising player in the fibrosis space with a mechanistically distinct platform.
View full company profile